1. A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1). (May 2018) Authors: Lindman, H.; Andersson, M.; Ahlgren, J.; Balslev, E.; Sverrisdottir, A.; Holmberg, S.B.; Bengtsson, N.O.; Jacobsen, E.H.; Jensen, A.B.; Hansen, J.; Tuxen, M.K.; Malmberg, L.; Villman, K.; Anderson, H.; Ejlertsen, B.; Bergh, J.; Blomqvist, C. Journal: European journal of cancer Issue: Volume 94(2018) Page Start: 79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Filaggrin loss‐of‐function mutations, atopic dermatitis and risk of actinic keratosis: results from two cross‐sectional studies. (6th March 2017) Authors: Andersen, Y.M.F.; Egeberg, A.; Balslev, E.; Jørgensen, C.L.T.; Szecsi, P.B.; Stender, S.; Kaae, J.; Linneberg, A.; Gislason, G.; Skov, L.; Elias, P.M.; Thyssen, J.P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 6(2017) Page Start: 1038 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Histopathologic characteristics in synchronous bilateral breast cancer patients: A nationwide Danish cohort study from 1999–2015. (April 2018) Authors: Mejdahl, M.K.; Kroman, N.; Balslev, E.; Wohlfahrt, J.; Melbye, M.; Tjønneland, A.; Holm, M. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Individuals with complete filaggrin deficiency may have an increased risk of squamous cell carcinoma. (1st June 2014) Authors: Kaae, J.; Szecsi, P.B.; Meldgaard, M.; Espersen, M.L.M.; Stender, S.; Johansen, J.D.; Bandier, J.; Thyssen, J.P.; Menné, T.; Nielsen, S.L.; Høgdall, E.; Balslev, E.; Skov, L. Journal: British journal of dermatology Issue: Volume 170:Number 6(2014:Jun.) Page Start: 1380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Individuals with complete filaggrin deficiency may have an increased risk of squamous cell carcinoma. (June 2014) Authors: Kaae, J.; Szecsi, P.B.; Meldgaard, M.; Espersen, M.L.M.; Stender, S.; Johansen, J.D.; Bandier, J.; Thyssen, J.P.; Menné, T.; Nielsen, S.L.; Høgdall, E.; Balslev, E.; Skov, L. Journal: British journal of dermatology Issue: Volume 170:Number 6(2014:Jun.) Page Start: 1380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Loss‐of‐function mutations in filaggrin gene and malignant melanoma: a case–control study. (12th September 2017) Authors: Thyssen, J.P.; Andersen, Y.M.F.; Balslev, E.; Szecsi, P.B.; Stender, S.; Kaae, J.; Linneberg, A.; Skov, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 2(2018) Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. Issue 1 (10th December 2019) Authors: Munck, F.; Clausen, E. W.; Balslev, E.; Kroman, N.; Tvedskov, T. F.; Holm‐Rasmussen, E. V. Journal: British journal of surgery Issue: Volume 107:Issue 1(2020) Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Risk factors for sentinel node metastases in patients with ductal carcinoma in situ in the breast. (April 2018) Authors: Holm-Rasmussen, E.V.; Jensen, M.B.; Balslev, E.; Kroman, N.; Filtenborg Tvedskov, T. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗